Cargando…

(695) Predictors of Omicron Covid-19 Severity in a Large Lung Transplant Cohort

PURPOSE: Lung transplant recipients (LTR) are at higher risk of developing allograft dysfunction/serious illness following COVID-19 infection. A national lock-down, plus a multi-pronged prevention strategy started early in the COVID-19 pandemic saw only 12 (2%) LTR in our cohort become COVID-19 posi...

Descripción completa

Detalles Bibliográficos
Autores principales: Levvey, B., Ennis, S., Shingles, H., Gardiner, B., Snell, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068039/
http://dx.doi.org/10.1016/j.healun.2023.02.709
_version_ 1785018601807282176
author Levvey, B.
Ennis, S.
Shingles, H.
Gardiner, B.
Snell, G.
author_facet Levvey, B.
Ennis, S.
Shingles, H.
Gardiner, B.
Snell, G.
author_sort Levvey, B.
collection PubMed
description PURPOSE: Lung transplant recipients (LTR) are at higher risk of developing allograft dysfunction/serious illness following COVID-19 infection. A national lock-down, plus a multi-pronged prevention strategy started early in the COVID-19 pandemic saw only 12 (2%) LTR in our cohort become COVID-19 positive (COV+) till end of 2021. In 2022, end of compulsory lockdowns and the arrival of the omicron variant resulted in a further 204 (33%) LTR becoming COV+. This paper investigates predictors of COVID-19 severity and outcomes in a large LTR cohort. METHODS: Demographic, COVID treatment and outcome data on all COV+ LTR between Mar 2020- Sept 2022 were collected prospectively. LTR with higher NIH COVID-19 severity (score ≥ 3) were compared to lower severity using logistic regression. RESULTS: 216 from 650 LTR had 224 COV+ infections. Median age was 60yrs, 55% were male, 98% were bilateral LTR. Median time from LTx to COV+ was 5.2yrs (IQR 2.7-10). 193 (85%) had received ≥ 3 COVID vaccines and 38 (17%) evusheld. COVID treatment was commenced within 48hrs in 151 (70%). 42 (19%) COV+ LTR were hospitalized, 8 (4%) admitted to ICU. Only 13/216 (6%) LTR had a COVID severity score ≥ 3, however 8 /13 (62%) of these died- 5 deaths (at mean 11 days) due to COVID pneumonitis, 3 deaths (at mean 61 days), due to COVID complications. Results from logistic regression analysis to determine risk factors for COVID severity are displayed in Table 1. Predictors of COVID severity were increased BMI, chronic kidney disease stage 4/5, <3 vaccinations, and absence of treatment with remdesivir at time of COV+ diagnosis. Surprisingly, age and CLAD diagnosis did not predict a poor outcome. CONCLUSION: Vaccination prevention and remdesivir treatment proved potent omicron COVID management strategies. In an evolving COVID environment, rapid patient communication tools were critical to optimizing care. Less morbidity and mortality were seen than previously described. Patients with chronic kidney disease and obesity are a high risk cohort that should be targeted in future COVID-19 waves.
format Online
Article
Text
id pubmed-10068039
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-100680392023-04-03 (695) Predictors of Omicron Covid-19 Severity in a Large Lung Transplant Cohort Levvey, B. Ennis, S. Shingles, H. Gardiner, B. Snell, G. J Heart Lung Transplant Article PURPOSE: Lung transplant recipients (LTR) are at higher risk of developing allograft dysfunction/serious illness following COVID-19 infection. A national lock-down, plus a multi-pronged prevention strategy started early in the COVID-19 pandemic saw only 12 (2%) LTR in our cohort become COVID-19 positive (COV+) till end of 2021. In 2022, end of compulsory lockdowns and the arrival of the omicron variant resulted in a further 204 (33%) LTR becoming COV+. This paper investigates predictors of COVID-19 severity and outcomes in a large LTR cohort. METHODS: Demographic, COVID treatment and outcome data on all COV+ LTR between Mar 2020- Sept 2022 were collected prospectively. LTR with higher NIH COVID-19 severity (score ≥ 3) were compared to lower severity using logistic regression. RESULTS: 216 from 650 LTR had 224 COV+ infections. Median age was 60yrs, 55% were male, 98% were bilateral LTR. Median time from LTx to COV+ was 5.2yrs (IQR 2.7-10). 193 (85%) had received ≥ 3 COVID vaccines and 38 (17%) evusheld. COVID treatment was commenced within 48hrs in 151 (70%). 42 (19%) COV+ LTR were hospitalized, 8 (4%) admitted to ICU. Only 13/216 (6%) LTR had a COVID severity score ≥ 3, however 8 /13 (62%) of these died- 5 deaths (at mean 11 days) due to COVID pneumonitis, 3 deaths (at mean 61 days), due to COVID complications. Results from logistic regression analysis to determine risk factors for COVID severity are displayed in Table 1. Predictors of COVID severity were increased BMI, chronic kidney disease stage 4/5, <3 vaccinations, and absence of treatment with remdesivir at time of COV+ diagnosis. Surprisingly, age and CLAD diagnosis did not predict a poor outcome. CONCLUSION: Vaccination prevention and remdesivir treatment proved potent omicron COVID management strategies. In an evolving COVID environment, rapid patient communication tools were critical to optimizing care. Less morbidity and mortality were seen than previously described. Patients with chronic kidney disease and obesity are a high risk cohort that should be targeted in future COVID-19 waves. Published by Elsevier Inc. 2023-04 2023-04-03 /pmc/articles/PMC10068039/ http://dx.doi.org/10.1016/j.healun.2023.02.709 Text en Copyright © 2023 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Levvey, B.
Ennis, S.
Shingles, H.
Gardiner, B.
Snell, G.
(695) Predictors of Omicron Covid-19 Severity in a Large Lung Transplant Cohort
title (695) Predictors of Omicron Covid-19 Severity in a Large Lung Transplant Cohort
title_full (695) Predictors of Omicron Covid-19 Severity in a Large Lung Transplant Cohort
title_fullStr (695) Predictors of Omicron Covid-19 Severity in a Large Lung Transplant Cohort
title_full_unstemmed (695) Predictors of Omicron Covid-19 Severity in a Large Lung Transplant Cohort
title_short (695) Predictors of Omicron Covid-19 Severity in a Large Lung Transplant Cohort
title_sort (695) predictors of omicron covid-19 severity in a large lung transplant cohort
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068039/
http://dx.doi.org/10.1016/j.healun.2023.02.709
work_keys_str_mv AT levveyb 695predictorsofomicroncovid19severityinalargelungtransplantcohort
AT enniss 695predictorsofomicroncovid19severityinalargelungtransplantcohort
AT shinglesh 695predictorsofomicroncovid19severityinalargelungtransplantcohort
AT gardinerb 695predictorsofomicroncovid19severityinalargelungtransplantcohort
AT snellg 695predictorsofomicroncovid19severityinalargelungtransplantcohort